|
US5019368A
(en)
|
1989-02-23 |
1991-05-28 |
Cancer Biologics, Inc. |
Detection of necrotic malignant tissue and associated therapy
|
|
US5283173A
(en)
|
1990-01-24 |
1994-02-01 |
The Research Foundation Of State University Of New York |
System to detect protein-protein interactions
|
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
|
TW225528B
(enExample)
|
1992-04-03 |
1994-06-21 |
Ciba Geigy Ag |
|
|
US5641875A
(en)
|
1993-09-30 |
1997-06-24 |
University Of Pennsylvania |
DNA encoding chimeric IgG Fc receptor
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
SI9620103A
(sl)
|
1995-07-06 |
1998-10-31 |
Novartis Ag |
Pirolopirimidini in postopki za njihovo pripravo
|
|
GB9518220D0
(en)
|
1995-09-06 |
1995-11-08 |
Medical Res Council |
Checkpoint gene
|
|
US5760041A
(en)
|
1996-02-05 |
1998-06-02 |
American Cyanamid Company |
4-aminoquinazoline EGFR Inhibitors
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
EA001595B1
(ru)
|
1996-04-12 |
2001-06-25 |
Варнер-Ламберт Компани |
Необратимые ингибиторы тирозинкиназ
|
|
CA2258548C
(en)
|
1996-06-24 |
2005-07-26 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
|
EP0954315A2
(en)
|
1996-09-13 |
1999-11-10 |
Sugen, Inc. |
Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
|
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
JPH10234372A
(ja)
|
1997-02-27 |
1998-09-08 |
Boehringer Mannheim Corp |
キメラ受容体を有する細胞とその作成方法、並びに その利用
|
|
CO4940418A1
(es)
|
1997-07-18 |
2000-07-24 |
Novartis Ag |
Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
|
|
US20020004041A1
(en)
|
1999-02-19 |
2002-01-10 |
Albert Matthew L. |
Methods for abrogating a cellular immune response
|
|
DE1257584T1
(de)
|
2000-02-24 |
2003-05-28 |
Lilly Co Eli |
Humanisierte antikörper, die amyloid beta peptid demarkieren
|
|
AU2001240076A1
(en)
|
2000-03-08 |
2001-09-17 |
National Jewish Medical And Research Center |
Phosphatidyl serine receptors and uses thereof
|
|
WO2001068709A1
(en)
|
2000-03-14 |
2001-09-20 |
Idec Pharmaceuticals Corporation |
Antibodies that bind phosphatidyl serine and a method of their use
|
|
US20030072743A1
(en)
|
2000-05-05 |
2003-04-17 |
Matthew Albert |
Genetic manipulation of phagocytes for modulation of antigen processing and the immune response therefrom
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US7553939B2
(en)
|
2001-06-29 |
2009-06-30 |
The Board Of Trustees Of The Leland Stanford Junior University |
T cell regulatory genes and methods of use thereof
|
|
US8709412B2
(en)
*
|
2001-06-29 |
2014-04-29 |
The Board Of Trustees Of The Leland Stanford Junior University |
Modulation of TIM receptor activity in combination with cytoreductive therapy
|
|
PT1478648E
(pt)
|
2002-02-01 |
2014-07-15 |
Ariad Pharma Inc |
Compostos contendo fósforo e suas utilizações
|
|
US20060002940A1
(en)
|
2002-03-15 |
2006-01-05 |
Jennifer Stevenson |
Method of immunotherapy
|
|
US7247303B2
(en)
|
2002-07-15 |
2007-07-24 |
Board Of Regents, The University Of Texas System |
Selected antibody CDRs for binding to aminophospholipids
|
|
AU2003209753A1
(en)
|
2003-01-27 |
2004-08-23 |
Crucell Holland B.V. |
Internalising human binding molecules against cd72
|
|
WO2005019429A2
(en)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
WO2005047860A2
(en)
|
2003-11-08 |
2005-05-26 |
Elan Pharmaceuticals, Inc. |
Antibodies to alpha-synuclein
|
|
TW200539890A
(en)
|
2004-03-12 |
2005-12-16 |
Brigham & Womens Hospital |
Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
|
|
KR20070037570A
(ko)
|
2004-03-24 |
2007-04-05 |
텔로스 파마슈티칼스 인코포레이티드 |
백신에 대한 면역반응을 향상시키는 보강제로서의 조성물및 이의 사용 방법
|
|
GB0414055D0
(en)
|
2004-06-23 |
2004-07-28 |
Univ Edinburgh |
Specific binding members and uses thereof
|
|
CN101146826A
(zh)
|
2005-01-24 |
2008-03-19 |
得克萨斯大学体系董事会 |
与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
|
|
US20060257359A1
(en)
|
2005-02-28 |
2006-11-16 |
Cedric Francois |
Modifying macrophage phenotype for treatment of disease
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
RU2429244C2
(ru)
|
2006-03-23 |
2011-09-20 |
Байоарктик Ньюросайенс Аб |
Улучшенные селективные в отношении протофибрилл антитела и их применение
|
|
EP2046833B9
(en)
|
2006-07-14 |
2014-02-19 |
AC Immune S.A. |
Humanized antibody against amyloid beta
|
|
US8119772B2
(en)
|
2006-09-29 |
2012-02-21 |
California Institute Of Technology |
MART-1 T cell receptors
|
|
EP2205242B1
(en)
|
2007-09-12 |
2015-04-15 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック， インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
|
CN102317316B
(zh)
|
2008-12-19 |
2014-08-13 |
帕尼玛制药股份公司 |
人抗α突触核蛋白自身抗体
|
|
WO2010129917A2
(en)
|
2009-05-08 |
2010-11-11 |
Vaccinex, Inc. |
Anti-cd100 antibodies and methods for using the same
|
|
WO2011085070A2
(en)
|
2010-01-06 |
2011-07-14 |
Virginia Tech Intellectual Properties, Inc. |
Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
|
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
US10391126B2
(en)
|
2011-11-18 |
2019-08-27 |
Board Of Regents, The University Of Texas System |
CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
|
|
WO2013192294A1
(en)
|
2012-06-20 |
2013-12-27 |
Boston 3T Biotechnologies, Inc. |
Cellular therapies for treating and preventing cancers and other immune system disorders
|
|
BR122020002986A8
(pt)
|
2012-08-20 |
2023-04-18 |
Seattle Childrens Hospital Dba Seattle Childrens Res Inst |
Método e composições para imunoterapia celular
|
|
AU2013329186B2
(en)
|
2012-10-10 |
2019-02-14 |
Sangamo Therapeutics, Inc. |
T cell modifying compounds and uses thereof
|
|
US20140162290A1
(en)
|
2012-11-22 |
2014-06-12 |
Riken |
Probe for detecting dead cell
|
|
EP2970985A1
(en)
|
2013-03-14 |
2016-01-20 |
Fred Hutchinson Cancer Research Center |
Compositions and methods to modify cells for therapeutic objectives
|
|
WO2015066262A1
(en)
|
2013-11-04 |
2015-05-07 |
Trustees Of Dartmouth College |
Methods for preventing toxicity of adoptive cell therapy
|
|
KR102375998B1
(ko)
|
2014-02-14 |
2022-03-21 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
키메라 항원 수용체 및 제조방법
|
|
MX375379B
(es)
|
2014-05-29 |
2025-03-06 |
Us Health |
Receptores de celulas t anti - papilomavirus 16 e7 humano.
|
|
TWI734975B
(zh)
|
2014-06-27 |
2021-08-01 |
美商Ｃ２Ｎ醫療診斷有限責任公司 |
人類化抗-tau抗體
|
|
EP4205749A1
(en)
*
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
US20170151281A1
(en)
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
EP3288568A4
(en)
|
2015-04-30 |
2019-01-02 |
University of Southern California |
Secretory tnt car cell immunotherapy
|
|
PL3298033T5
(pl)
|
2015-05-18 |
2023-10-30 |
TCR2 Therapeutics Inc. |
Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych
|
|
US11116795B2
(en)
|
2015-07-10 |
2021-09-14 |
The Trustees Of The University Of Pennsylvania |
Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor
|
|
IL315940A
(en)
|
2015-07-28 |
2024-11-01 |
Univ Pennsylvania |
Altered monocytes/macrophages expressing chimeric antigen receptors and their uses
|
|
US10093717B2
(en)
|
2015-08-07 |
2018-10-09 |
Shenzhen In Vivo Biomedicine Technology Limited Company |
Chimeric antigen receptor containing a toll-like receptor intracellular domain
|
|
WO2017025944A2
(en)
|
2015-08-13 |
2017-02-16 |
Brigham Young University |
Macrophage car (moto-car) in imunotherapy
|
|
US11352439B2
(en)
|
2015-08-13 |
2022-06-07 |
Kim Leslie O'Neill |
Macrophage CAR (MOTO-CAR) in immunotherapy
|
|
WO2017032293A1
(zh)
|
2015-08-21 |
2017-03-02 |
科济生物医药（上海）有限公司 |
抗间皮素全人抗体以及靶向间皮素的免疫效应细胞
|
|
BR112018008442A2
(pt)
|
2015-11-05 |
2018-11-06 |
Juno Therapeutics Inc |
receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
|
|
WO2017083700A1
(en)
|
2015-11-13 |
2017-05-18 |
The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas |
Ligand-guided phagocytosis based therapy for treatment of alzheimer's disease and other neurodegenerative diseases
|
|
US20180186855A1
(en)
|
2016-03-23 |
2018-07-05 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
|
US10875919B2
(en)
|
2016-04-26 |
2020-12-29 |
Alector Llc |
Chimeric receptors and methods of use thereof
|
|
CA3025516A1
(en)
|
2016-05-27 |
2017-11-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Flt3-specific chimeric antigen receptors and methods using same
|
|
CN107522786A
(zh)
|
2016-06-20 |
2017-12-29 |
深圳市体内生物医药科技有限公司 |
一种分子、表达其的细胞及其制备方法和用途
|
|
WO2018031419A1
(en)
|
2016-08-12 |
2018-02-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for enhancing immunogenic cross-presentation of tumor antigens
|
|
AU2017335634A1
(en)
|
2016-09-27 |
2019-03-14 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptor molecules
|
|
EP3568416A4
(en)
|
2017-01-13 |
2020-07-08 |
Celdara Medical, LLC |
TIM-1 TARGETED CHIMERIC ANTIGENIC RECEPTORS
|
|
US10415017B2
(en)
|
2017-05-17 |
2019-09-17 |
Thunder Biotech, Inc. |
Transgenic macrophages, chimeric antigen receptors, and associated methods
|
|
JP7164598B2
(ja)
|
2017-05-17 |
2022-11-01 |
サンダー・バイオテック・インコーポレイテッド |
トランスジェニックマクロファージ、キメラ抗原受容体、及び関連する方法
|
|
WO2018220224A1
(en)
|
2017-06-02 |
2018-12-06 |
Medirista Biotechnologies Ab |
Lipid-related antigens and antibodies directed against them
|
|
EP4714966A2
(en)
|
2017-09-26 |
2026-03-25 |
Cero Therapeutics Holdings, Inc. |
Chimeric engulfment receptor molecules and methods of use
|
|
US20210186917A1
(en)
|
2017-10-17 |
2021-06-24 |
The Translational Genomics Research Institute |
Trem2 agonists for the stimulation of microglia and methods of identification
|
|
GB201717974D0
(en)
|
2017-10-31 |
2017-12-13 |
Univ Court Of The Univ Of Aberdeen |
Modified receptors
|
|
US11866731B2
(en)
|
2017-11-10 |
2024-01-09 |
Chineo Medical Technology Co., Ltd |
Modified immune cells and uses thereof
|
|
JP7387613B2
(ja)
|
2018-02-09 |
2023-11-28 |
ザ トラスティーズ オブ ダートマス カレッジ |
神経変性疾患及び障害の治療のためのキメラ抗原受容体
|
|
WO2019191332A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
|
|
CA3093969A1
(en)
|
2018-03-28 |
2019-10-03 |
Cero Therapeutics, Inc. |
Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
|
|
MX2020010241A
(es)
|
2018-03-28 |
2020-10-16 |
Cero Therapeutics Inc |
Composiciones de inmunoterapia celular y usos de las mismas.
|
|
EP3774906A1
(en)
|
2018-03-28 |
2021-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
CA3102641A1
(en)
|
2018-06-22 |
2019-12-26 |
Kite Pharma, Inc. |
Chimeric transmembrane proteins and uses thereof
|
|
WO2020097193A1
(en)
|
2018-11-06 |
2020-05-14 |
The Regents Of The University Of California |
Chimeric antigen receptors for phagocytosis
|
|
US20230158071A1
(en)
|
2018-12-07 |
2023-05-25 |
Crage Medical Co., Limited |
Tumor combined immunotherapy
|
|
EP3962497A4
(en)
|
2019-04-30 |
2023-01-18 |
Myeloid Therapeutics, Inc. |
GENETICALLY ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
|
|
JP2022539587A
(ja)
|
2019-07-03 |
2022-09-12 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
Ｂ細胞悪性腫瘍の処置のために細胞表面マーカーｃｄ７２を標的とする免疫療法
|
|
EP4038097A1
(en)
|
2019-10-03 |
2022-08-10 |
Cero Therapeutics, Inc. |
Chimeric tim4 receptors and uses thereof
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
US20210253696A1
(en)
|
2020-01-21 |
2021-08-19 |
Cero Therapeutics, Inc. |
Bivalent chimeric engulfment receptors and uses thereof
|
|
WO2022036265A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Chimeric tim receptors and uses thereof
|
|
WO2022036287A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Anti-cd72 chimeric receptors and uses thereof
|
|
WO2022036285A1
(en)
|
2020-08-14 |
2022-02-17 |
Cero Therapeutics, Inc. |
Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
|
|
EP4376874B1
(en)
|
2021-07-28 |
2026-03-04 |
Cero Therapeutics Holdings, Inc. |
Chimeric tim4 receptors and uses thereof
|